Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com

Articles

Frontline Findings Put Fresh Focus on Immunotherapy in NSCLC

December 20th 2017

Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non

FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML

December 20th 2017

The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.

FDA Approves Frontline Cabozantinib for Advanced RCC

December 20th 2017

The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma.

Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer

December 14th 2017

The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,

Ivosidenib Shows High Single-Agent Activity for IDH1-mutant AML

December 13th 2017

The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Daratumumab Plus VMP New Standard of Care for Some Newly Diagnosed Myeloma Patients

December 12th 2017

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL

December 12th 2017

Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.

Acalabrutinib Highly Effective for Refractory MCL

December 11th 2017

Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.

Axi-Cel Responses Sustained With Longer Follow-Up for NHL

December 10th 2017

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

Ibrutinib/Venetoclax Combo Impresses in Early CLL Data

December 10th 2017

The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.

Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer

December 9th 2017

The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.

Pembrolizumab/Eribulin Efficacy Maintained for TNBC in Larger Dataset

December 9th 2017

Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.

Neoadjuvant Abemaciclib Active in Early Breast Cancer

December 8th 2017

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

Nab-Paclitaxel Shows Greatest Utility for TNBC

December 8th 2017

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

Frontline Atezolizumab Regimen Improves PFS in NSCLC

December 7th 2017

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Sacituzumab Govitecan Highly Effective in Heavily Pretreated mTNBC

December 6th 2017

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.

Atezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC

November 20th 2017

The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

Pembrolizumab, Atezolizumab New Standards for Bladder Cancer

November 18th 2017

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy

November 17th 2017

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.